FUDANZHANGJIANG (01349.HK): Bladder Cancer Drug NDA Accepted in China

On 19 November 2026, FUDANZHANGJIANG (01349.HK) said NMPA accepted its filing for aminolevulinic acid hydrochloride granules used in bladder cancer surgery.

NewTimeSpace News: On 19 November 2026, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349.HK) said it received an acceptance notice from the NMPA for its abbreviated new drug application for aminolevulinic acid hydrochloride granules, developed for intraoperative visualization of non-muscular invasive bladder cancer.

The drug has a strength of 1.5 g per sachet and is filed as a class 3 chemical drug for domestic manufacturing and marketing authorization, under acceptance number CYHS2602848. The company obtained clinical trial approval in February 2024 and started a Phase III confirmatory trial in March 2025 to evaluate the efficacy and safety of oral administration for fluorescence-guided tumour resection; the trial has been completed.

NMIBC accounts for about 75% of bladder cancer cases, and transurethral resection of bladder tumour is the preferred surgical treatment, with residual tumour a major cause of recurrence, the company said. Approval remains subject to technical review, on-site inspection and administrative approval, and the timing and outcome are uncertain; the acceptance is not expected to have a material impact on near-term results.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.